Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41E6D | ISIN: US3207034089 | Ticker-Symbol:
NASDAQ
02.10.25 | 21:42
1,570 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CALIDI BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CALIDI BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CALIDI BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.09.Calidi Biotherapeutics, Inc. - 8-K, Current Report2
29.08.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
22.08.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
22.08.Calidi Biotherapeutics closes $6.9 million public offering2
CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
22.08.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option2
20.08.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering3
15.08.Calidi files to sell 1.2M common stock units1
15.08.Calidi Biotherapeutics, Inc. - S-1, General form for registration of securities1
14.08.Calidi Biotherapeutics, Inc. - 8-K, Current Report2
11.08.Calidi Biotherapeutics GAAP EPS of -$1.991
08.08.Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report1
08.08.Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights233Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune...
► Artikel lesen
07.08.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
01.08.RedChip Companies, Inc.: Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV519ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip...
► Artikel lesen
29.07.FDA grants fast track designation to Calidi's CLD-201 for sarcoma3
25.07.Calidi announces reverse stock split, expected to begin trading on a 1-for-12 split adjusted basis4
25.07.Calidi Biotherapeutics, Inc. - 8-K, Current Report1
25.07.Calidi Biotherapeutics, Inc: Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025275SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted...
► Artikel lesen
22.07.Calidi Biotherapeutics, Inc: Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 242
10.07.Calidi Biotherapeutics, Inc. - 8-K, Current Report7
Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1